$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011128 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.54M	$17.69M	$64.99M
YoY Change	19.42%	15.5%	41.77%
Cost Of Revenue	$1.890M	$1.788M	$7.853M
YoY Change	-11.08%	-24.52%	23.45%
Gross Profit	$16.65M	$15.90M	$57.14M
YoY Change	24.26%	22.82%	44.72%
Gross Profit Margin	89.8%	89.89%	87.92%
Selling, General & Admin	$16.19M	$16.34M	$56.99M
YoY Change	24.85%	15.78%	23.97%
% of Gross Profit	97.27%	102.73%	99.75%
Research & Development	$946.3K	$651.5K	$4.132M
YoY Change	-28.17%	-36.99%	22.73%
% of Gross Profit	5.68%	4.1%	7.23%
Depreciation & Amortization	$133.0K	$1.095M	$456.1K
YoY Change	23.49%	34.47%	11.86%
% of Gross Profit	0.8%	6.89%	0.8%
Operating Expenses	$18.18M	$16.13M	$61.35M
YoY Change	24.4%	1.06%	18.64%
Operating Profit	-$1.532M	-$226.0K	-$4.215M
YoY Change	25.93%	-92.5%	-65.54%
Interest Expense	$267.3K	-$36.45K	$475.8K
YoY Change	4455500.0%		67.09%
% of Operating Profit
Other Income/Expense, Net	-$267.3K		-$224.7K
YoY Change	4455500.0%		-86.82%
Pretax Income	-$1.799M	-$262.4K	-$4.440M
YoY Change	47.91%	-93.7%	-68.14%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.764M	-$237.2K	-$4.303M
YoY Change	49.77%	-94.22%	-45.79%
Net Earnings / Revenue	-9.52%	-1.34%	-6.62%
Basic Earnings Per Share	-$0.21		-$0.52
Diluted Earnings Per Share	-$0.21	-$0.03	-$0.52
COMMON SHARES
Basic Shares Outstanding	8.623M shares	8.538M shares	8.279M shares
Diluted Shares Outstanding	8.420M shares		8.279M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.828M	$5.147M	$5.147M
YoY Change	-61.19%	-42.55%	-42.55%
Cash & Equivalents	$2.828M	$5.147M
Short-Term Investments
Other Short-Term Assets	$911.6K	$608.4K	$608.4K
YoY Change	-47.86%	-44.92%	-44.92%
Inventory	$4.229M	$4.718M	$4.718M
Prepaid Expenses
Receivables	$9.218M	$8.533M	$8.533M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.19M	$19.01M	$19.01M
YoY Change	-9.58%	-7.81%	-7.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.191M	$1.258M	$3.253M
YoY Change	-10.86%	-11.19%	46.35%
Goodwill	$3.602M	$3.602M
YoY Change	0.0%	0.0%
Intangibles	$43.95M	$44.93M
YoY Change	42.53%	42.58%
Long-Term Investments	$3.084M	$3.084M	$3.084M
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$53.73M	$54.87M	$54.87M
YoY Change	31.17%	35.74%	35.74%
TOTAL ASSETS
Total Short-Term Assets	$17.19M	$19.01M	$19.01M
Total Long-Term Assets	$53.73M	$54.87M	$54.87M
Total Assets	$70.91M	$73.87M	$73.87M
YoY Change	18.25%	21.03%	21.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.279M	$2.002M	$2.002M
YoY Change	-29.78%	43.74%	40.31%
Accrued Expenses	$9.559M	$10.09M	$10.09M
YoY Change	18.1%	-1.28%	-1.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$928.6K	$580.4K	$580.4K
YoY Change
Total Short-Term Liabilities	$12.75M	$13.77M	$13.77M
YoY Change	20.23%	7.51%	7.51%
LONG-TERM LIABILITIES
Long-Term Debt	$8.768M	$9.113M	$9.113M
YoY Change
Other Long-Term Liabilities	$2.778M	$2.723M	$6.402M
YoY Change	-53.91%	-54.65%	-1.64%
Total Long-Term Liabilities	$15.15M	$15.52M	$15.52M
YoY Change	92.15%	138.36%	138.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.75M	$13.77M	$13.77M
Total Long-Term Liabilities	$15.15M	$15.52M	$15.52M
Total Liabilities	$27.90M	$29.28M	$29.04M
YoY Change	50.91%	51.61%	51.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.90M	-$28.04M
YoY Change	20.01%	19.84%
Common Stock	$73.19M	$72.87M
YoY Change	10.0%	11.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.29M	$44.83M	$44.83M
YoY Change
Total Liabilities & Shareholders Equity	$70.91M	$73.87M	$73.87M
YoY Change	18.25%	21.03%	21.03%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.764M	-$237.2K	-$4.303M
YoY Change	49.77%	-94.22%	-45.79%
Depreciation, Depletion And Amortization	$133.0K	$1.095M	$456.1K
YoY Change	23.49%	34.47%	11.86%
Cash From Operating Activities	-$1.594M	-$845.6K	-$3.246M
YoY Change	-8.44%	31.09%	-41.57%
INVESTING ACTIVITIES
Capital Expenditures	$65.82K	$55.25K	$265.2K
YoY Change	137.57%	3.52%	80.42%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$2.100K	-$9.942M
YoY Change	-100.0%	-99.35%	259.62%
Cash From Investing Activities	-$65.82K	-$57.35K	-$10.21M
YoY Change	143.27%	-84.79%	190.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$658.8K	-188.9K	$9.641M
YoY Change	-787.6%	-37.95%	-1636.81%
NET CHANGE
Cash From Operating Activities	-$1.594M	-845.6K	-$3.246M
Cash From Investing Activities	-$65.82K	-57.35K	-$10.21M
Cash From Financing Activities	-$658.8K	-188.9K	$9.641M
Net Change In Cash	-$2.319M	-1.092M	-$3.812M
YoY Change	38.65%	-17.69%	-60.68%
FREE CASH FLOW
Cash From Operating Activities	-$1.594M	-$845.6K	-$3.246M
Capital Expenditures	$65.82K	$55.25K	$265.2K
Free Cash Flow	-$1.660M	-$900.8K	-$3.511M
YoY Change	-6.15%	28.98%	-38.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities		usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities		usd
CY2023	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive		usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2022Q4	SMTI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies		usd
CY2022Q4	SMTI	Deferred Tax Assets Acquistion Liability DeferredTaxAssetsAcquistionLiability		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements		usd
CY2022Q4	SMTI	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability		usd
CY2022Q4	SMTI	Deferred Tax Liabilities Other Temporary Differences DeferredTaxLiabilitiesOtherTemporaryDifferences		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
CY2022	SMTI	Income Tax Reconciliation Fair Value Adjustments IncomeTaxReconciliationFairValueAdjustments		usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjusted For Expiration IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration		usd
CY2023	SMTI	Income Tax Reconciliation Expense Equity Method Investment Loss IncomeTaxReconciliationExpenseEquityMethodInvestmentLoss		usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment		usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment		usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2022	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjustments IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustments		usd
CY2022	SMTI	Income Tax Reconciliation Income Tax Expense Intangibles IncomeTaxReconciliationIncomeTaxExpenseIntangibles		usd
CY2022	SMTI	Income Tax Reconciliation Income Tax Expense Other True Ups IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps		usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	151156822	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8622805	shares
CY2023	dei	Auditor Firm AuditorFirmId	410
CY2023	dei	Auditor Name AuditorName	Weaver and Tidwell, L.L.P
CY2023	dei	Auditor Location AuditorLocation	Austin, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5147216	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8958995	usd
CY2023Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2022Q4	SMTI	Royalty Receivable RoyaltyReceivable	99594	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4717533	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3549000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	608411	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1104611	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	19005869	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20616509	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44926061	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31509980	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1995204	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	806402	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	54865280	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40418877	usd
CY2023Q4	us-gaap	Assets Assets	73871149	usd
CY2022Q4	us-gaap	Assets Assets	61035386	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7676770	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7758284	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2047678	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2144475	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1100000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1162880	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361185	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313933	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13767877	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12806309	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2723001	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6003811	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1737445	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	505291	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1941686	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15515255	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6509102	usd
CY2023Q4	us-gaap	Liabilities Liabilities	29283132	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19315411	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8535239	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8535239	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8299957	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8299957	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8535	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8300	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72860556	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65213987	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28036814	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23394757	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44832277	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41827530	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-244260	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-107555	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73871149	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61035386	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64989842	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45842845	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	6360851	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56994753	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4132425	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3367032	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3675026	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371068	usd
CY2023	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	3449895	usd
CY2022	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	-284746	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	61352309	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	51999174	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4215153	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12517180	usd
CY2023	us-gaap	Interest Expense InterestExpense	475783	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	251034	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1040311	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-224749	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1419944	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4439902	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13937124	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-4439902	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-136705	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-154831	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4303197	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7937497	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8278949	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8278949	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7906794	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7906794	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	11125872	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4612645	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3790817	usd
CY2022	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-407346	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	220000	usd
CY2022	SMTI	Minority Interest Of Dissolution Of Investment MinorityInterestOfDissolutionOfInvestment	758311	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3442722	usd
CY2023	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-135794	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3089645	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	911371	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-4439902	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-4439902	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3675026	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371068	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2634	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	202941	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	280000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	406812	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	540090	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3442722	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2702633	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	342972	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	263518	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	251034	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1040311	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5844796	usd
CY2023	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	98926	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5138	usd
CY2023	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	3449895	usd
CY2022	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	-284746	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1821895	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2250223	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-90148	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	18761	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1545339	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	517271	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-496200	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	159592	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	531380	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-301966	usd
CY2023	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	43768	usd
CY2022	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-121781	usd
CY2023	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	-739645	usd
CY2022	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	1156073	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-81513	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2994512	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-252366	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-263370	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3245556	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5554870	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	265246	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147015	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1549	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	600000	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	9942750	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2516164	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10207346	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3511630	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	9688341	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	911371	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-135794	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-407346	usd
CY2023	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities	822795	usd
CY2022	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	220000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9641123	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-627346	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3811779	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9693846	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5147216	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	283948	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	206	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1531773	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	3089645	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	15738518	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	3759642	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	6882151	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1803440	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zMKOZRSuGIdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_828_z9ePQBUM28lf">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies are designed to achieve the Company’s goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zdzC8WVI8CF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zKl0UExlEnP9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64989842	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45842845	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	202941	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	280000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	528030	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	325089	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3820	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4761	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	406812	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	540090	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	446917	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	523832	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2454080	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2156422	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1196124	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	739986	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023	us-gaap	Depreciation Depreciation	456138	usd
CY2022	us-gaap	Depreciation Depreciation	407769	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7166691	usd
CY2023	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Additions BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAdditions	893000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3449895	usd
CY2023	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Revaluation Of Earnout Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability	-94000	usd
CY2023	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Settlements BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements	-692795	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3823001	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	162743	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	16792037	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000.0	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	9750000	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Equity Shares AssetAcquisitionConsiderationTransferredEquityShares	73809	shares
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Stock Closing Consideration AssetAcquisitionConsiderationTransferredFairValueOfStockClosingConsideration	3089645	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Installment Payments AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments	2040808	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Cash Paid For Inventory AssetAcquisitionConsiderationTransferredCashPaidForInventory	30007	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Petito Services Defined Payments AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments	825834	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	893000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	3601781	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y6M
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3218888	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1963299	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3889804	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3889804	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3872548	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3758696	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3725454	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	25789755	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44926061	usd
CY2023Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q4	us-gaap	Investments Investments	3084278	usd
CY2022Q4	us-gaap	Investments Investments	3084278	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1995204	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2098630	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	434066	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	297136	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	380576	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	296988	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	505017	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	532053	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	379529	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	297947	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	295689	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	604050	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2614285	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	515655	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2098630	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361185	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1737445	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076	pure
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	5138	usd
CY2022Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	0	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	9693480	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	580357	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1625000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1950000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1950000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	3644643	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2023Q4	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	56520	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Noncurrent Deferred Finance Costs AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts	0	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5138	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	us-gaap	Cash Cash	693000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	100829	shares
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	4045377	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3442722	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2702633	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1038183	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2877664	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	181102	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.89
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	118912	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	39.14
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	137720	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	23.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	18083	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	33.66
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	144211	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	34.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.65
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52299	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.41
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	93892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2023	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
CY2023	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5800000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	55700000	usd
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27000000.0	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	expire between 2024 and 2037
CY2023	SMTI	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsAmount	28700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12467570	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6818547	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2119193	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	707076	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	711598	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	232250	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	528148	usd
CY2023Q4	SMTI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	512668	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	221028	usd
CY2023Q4	SMTI	Deferred Tax Assets Acquistion Liability DeferredTaxAssetsAcquistionLiability	176629	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	129924	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	92286	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	109176	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	43678	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	203340	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26102	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17179274	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7919939	usd
CY2023Q4	SMTI	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	6180688	usd
CY2022Q4	SMTI	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	5919626	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	487402	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	424423	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	26903	usd
CY2023Q4	SMTI	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	130802	usd
CY2023Q4	SMTI	Deferred Tax Liabilities Other Temporary Differences DeferredTaxLiabilitiesOtherTemporaryDifferences	166712	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9789247	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1973410	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	903220	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2851758	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	226714	usd
CY2023	SMTI	Income Tax Reconciliation Fair Value Adjustments IncomeTaxReconciliationFairValueAdjustments	819270	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	557168	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	249516	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-118765	usd
CY2022	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjusted For Expiration IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration	-46936	usd
CY2022	SMTI	Income Tax Reconciliation Expense Equity Method Investment Loss IncomeTaxReconciliationExpenseEquityMethodInvestmentLoss	79723	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	4843	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	707076	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-329829	usd
CY2023	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjustments IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustments	5148128	usd
CY2023	SMTI	Income Tax Reconciliation Income Tax Expense Intangibles IncomeTaxReconciliationIncomeTaxExpenseIntangibles	720407	usd
CY2023	SMTI	Income Tax Reconciliation Income Tax Expense Other True Ups IncomeTaxReconciliationIncomeTaxExpenseOtherTrueUps	230474	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-673449	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7813167	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3657431	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd

Files In Submission

Name	View Source	Status
0001493152-24-011128-index-headers.html	Edgar Link	pending
0001493152-24-011128-index.html	Edgar Link	pending
0001493152-24-011128.txt	Edgar Link	pending
0001493152-24-011128-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20231231.xsd	Edgar Link	pending
smti-20231231_def.xml	Edgar Link	unprocessable
smti-20231231_lab.xml	Edgar Link	unprocessable
smti-20231231_pre.xml	Edgar Link	unprocessable
smti-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2024 Q1 Form 10-K Financial Statement

#000149315224011128 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2024 Q1 Form 10-K Financial Statement

#000149315224011128 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti